Insilico Medicine
Business Services · Massachusetts, United States · 201-500 Employees
View Company Info for Free
Overview
Headquarters
1000 Massachusetts Ave Ste 126, Cambridg...Website
www.insilico.comRevenue
$63.4 MillionIndustry
ZI Rank: 3
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
3
3
1
1
2
3
About Insilico Medicine
Insilico Medicine, an end-to-end artificial intelligence-driven drug discovery company, is developing artificial intelligence platforms that utilize deep generative models, reinforcement learning, transformer, and other modern machine learning techniques for novel target discovery and generation of novel molecular structures with desired properties. It is developing breakthrough solutions for the discovery and development of innovative drugs for cancer, fibrosis, infectious diseases, autoimmune diseases, and aging-related diseases.Explore more
Insilico Medicine Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Insilico Medicine your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check out if Insilico Medicine is spiking on competitors!
Website visits: Recent activity has been detected on your website
Check if Insilico Medicine has recently received funding, and reach out quickly before it becomes old news!
Click to see if Insilico Medicine had a recent Job posting/layoffs
Earning: See what the market has to say on Insilico Medicine recently announced quarterly report
Funding: Get notified immidiatlly once Insilico Medicine has new funding data
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Congratulate Masked Content for being promoted to Masked Content at Insilico Medicine
Product Launch: Get notified when Insilico Medicine launches new products
Insilico Medicine, which may be a good buyer, showed buying intent in Masked Content Topic
Recommended Actions
Reach out to Masked Content who joined Insilico Medicine as Masked Content
Find 2 more new buyers
Company Profile Activity
Activity Insights
Insilico Medicine is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Insilico Medicine is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Insilico Medicine.
Insilico Medicine financials insights
Gather financial insights about Insilico Medicine, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2016
Private Equity
$2.8M
2017
Private Equity
$4M
2018
Series A
$6M
2019
Series B
$37M
2021
Series C
$255M
2022
Series D
$95M
2025
Series E
$110M
Insilico Medicine Tech Stack
A closer look at the technologies used by Insilico Medicine
Most Recent Scoops
Person-Based
Partnership, Medical Research, Pharmaceuticals, Artificial Intelligence
Person-Based
Events, Pharmaceuticals, Artificial Intelligence
Person-Based
Partnership
Person-Based
Business Development
Person-Based
Partnership, Medical Research
Insilico Medicine News & Media
Insilico Medicine Introduces Biological Age into Virtual Cell Research: Launches Virtual Aging Cell Webpage and Previews Multi-Agent Driven VAC Generation Platform
Following a decade of exploration from the 2014 NVIDIA GTC to the PreciousGPT model series, Insilico Medicine presents the industry's first multi-agent Virtual Aging Cell (VAC) platform with biological age as a core condition. CAMBRIDGE, Mass., Aug. 14, 2026 /PRNewswire/ -- Insilico...Insilico Medicine Nominates ISM0900, a Potent, AI-driven, Oral Lp(a) Inhibitor, as PCC for Management of Cardiovascular Risks
CAMBRIDGE, Mass., Aug. 12, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico"; HKEX: 3696), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, today announced the nomination of ISM0900, a potent, AI-driven, highly selective, orally available small molecule inhibitor of lipoprotein(a), or Lp(a), as a preclinical candidate (PCC) for the management of cardiovascular risks. Notably, this marks the company's 9th PCC nomination announced since 2026, showcasing theInsilico Medicine Nominates ISM0900, a Potent, AI-driven, Oral Lp(a) Inhibitor, as PCC for Management of Cardiovascular Risks
CAMBRIDGE, Mass., Aug. 12, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico"; HKEX: 3696), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, today announced the nomination of ISM0900, a potent, AI-driven, highly selective, orally available small...Insilico Medicine Announces 2026 Interim Earnings Conference Call Dates
CAMBRIDGE, Mass., Aug. 11, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico"; HKEX: 3696), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, today announced that it will hold conference calls to discuss its financial results for the six months ended...
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Insilico Medicine
Sign Up For FreeTo access detailed company insights
Insilico Medicine, an end-to-end artificial intelligence-driven drug discovery company, is developing artificial intelligence platforms that utilize deep generative models, reinforcement learning, transformer, and other modern machine learning techniques for novel target discovery and generation of novel molecular structures with desired properties... Read More
